

SAHA Patient: IV vs ORAL (200 mg/dose)

Patient #

Week 1 Week 2

1-OS-200

IV ORAL





FIG. 1



Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)




FIG. 2

SAHA Patients: ORAL /Cohort I (200 mg/dose)





FIG. 3

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS

Cohort I (200 mg/dose)



6-OS-200
(12-13-01)





FIG. 4

Protocol 01-021 (ORAL SAHA)

ARM A: SOLID TUMOR PATIENTS

Cohort IIa (400 mg/dose)



12/19/01




FIG. 5

SAHA Patients: ORAL/Cohort II (400 mg/dose)




FIG. 6

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)




FIG. 7

SAHA Patients: ORAL/Cohort II (400 mg/dose)





FIG. 8

Oral 200 mg vs. 400 mg (Fasting)




Fig. 9A

Oral 200 mg VS. 400 mg (no-fasting)




Fig. 9B

IV 200 mg VS. 400 mg





Fig. 9C


Apparent Half-life of the Oral Dose



Blue=200 mg group ($n=3-5$); yellow=400 mg group ($n=5-10$)

Fig. 10

AUC of the Oral Dose



Blue=200 mg group (n=3-5); yellow=400 mg group (n=5-10)

Fig. 11

Bioavailability

$F \sim 48\%$

□ ■







Fig. 12

Theta-2Theta (deg)

FIG. 13A






FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E

FIG. 14A





FIG. 14B






FIG. 14C





FIG. 14D

PerkinElmer Thermal Analysis



1) Hold for 1.0 min at 50.00°C

2) Heat from 50.00°C to 300.00°C at 10.00°C/min

FIG. 14E

FIG. 15

